What Trisk Bio does

Trisk Bio is a privately held contract development and manufacturing organization (CDMO) specializing in adeno-associated virus (AAV) production for preclinical gene therapy programs. The company operates manufacturing facilities in Stevenage, United Kingdom (headquarters at 5 Gunnels Wood Park) and Waltham, Massachusetts, employing 1–10 people. Founded in 2020, Trisk Bio focuses exclusively on fully scalable AAV manufacturing workflows spanning research-grade (1e13 vg) through non-human primate (NHP) grade (5e13–1e15 vg) production for all capsids and transgenes, eliminating the need for process redesign between scales.

The company's core service is bespoke Custom AAV Manufacturing, supported by four integrated sub-offerings: high-throughput optimization workflows that screen multiple capsid variants against a single transgene; custom process development preceding large-batch manufacturing; partial capsid purification for use as analytical reference material (for ddPCR, AUC, CD-MS, and viral genome sequencing controls); and analytical development. A 2026 integration of NanoMosaic's Tessie analytics platform into Trisk's workflows at both facilities is intended to enhance analytical precision and regulatory compliance. Trisk Bio also participates in Dyno Therapeutics' expanded Frontiers Program as the first manufacturing partner, manufacturing AI-engineered capsids including Dyno-yp2 for CNS delivery.

Trisk Bio generates revenue through project-based, quote-based B2B contract manufacturing engagements with gene therapy developers. Pricing is not publicly disclosed and varies with manufacturing scale, capsid type, transgene complexity, and analytical requirements, with project structures described as multi-year contracts. The company acquires customers via direct enterprise engagement initiated through its website, industry conferences such as Dyno's Genetic Agency Technology Conference, and referral channels through technology partners and capsid developers. Only one external funding event is disclosed, a seed round with Quiet Capital in January 2022, with no reported revenue figure.

Name

Trisk Bio

Legal name

Trisk Bio

Website

https://triskbio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Trisk Bio is a UK- and US-based contract manufacturer specializing in fully scalable preclinical AAV gene therapy manufacturing, serving biotech and pharma developers with research-grade to NHP-grade production, capsid optimization, and analytical services.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Manufacturing (AAV / Gene Therapy CDMO)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)

akta.pro secondary industries

Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Gene Therapy Analytical Testing & QC (potency, vg/ddPCR, infectivity, RCL/RCA) (HLAAACAK)

Keywords

• AAV contract manufacturing
• Gene therapy manufacturing
• Preclinical viral vector production
• Capsid optimisation services
• Biopharmaceutical CDMO

Headquarters

HQ city

Stevenage

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. AAV Contract Manufacturing: Trisk Bio generates revenue through contract manufacturing services for AAV gene therapies. Services include research grade AAV production (1e13 vg), NHP grade production (5e13-1e15 vg), custom process development, analytical development, and high-throughput optimization. Revenue is project-based and scales with manufacturing batch size and complexity.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Trisk Bio provides contract manufacturing of preclinical adeno-associated virus (AAV) vectors for gene therapy developers. Services span research grade (1e13 vg) to NHP grade (5e13–1e15 vg) AAV production for all capsids and transgenes, alongside custom process development, high-throughput capsid optimisation, and purification of partial capsid species for analytical reference material.

Product overview

Trisk Bio provides custom AAV manufacturing as a single unified service focused on bespoke scalable preclinical manufacturing of gene therapies. The core Custom AAV Manufacturing service combines four integrated sub-products: AAV Projects (encompassing high throughput optimisation, custom process development, and analytical development), Rapid optimisation workflows for capsid-transgene pair screening, Purify partials for reference material isolation, and Custom process development for scalable large batch manufacturing. Together these support all capsids and transgenes across research grade (1e13 vg) to NHP grade (5e13–1e15 vg) production.

Differentiator

Problem solved

Functional benefit

Products and services

• Custom AAV Manufacturing Bespoke scalable preclinical AAV manufacturing service covering research grade (1e13 vg) to NHP grade (5e13–1e15 vg) production for all capsids and transgenes, enabling affordable preclinical manufacturing for biotech and pharma gene therapy developers.
• Rapid Optimisation Workflows High throughput workflow enabling testing of a single transgene across multiple capsid variants with bespoke condition development for capsid and transgene pairs, supporting early discovery assessment and rapid progression to NHP studies.
• Custom Process Development Process development service ahead of large batch manufacturing, featuring high throughput upstream optimisation, upstream and downstream optimisation, and large batch manufacturing (1–4e14 vg NHP grade) using dPCR and mass photometry readouts.
• Purify Partials Purification service for isolating partially filled AAV capsids for use as reference material, supporting analytical method development including spike-ins for viral genome sequencing, ddPCR, AUC, CD-MS, and advanced safety, potency, and stability studies.
• AAV Projects Integrated service offering encompassing high throughput optimisation, custom process development, and analytical development for AAV gene therapy manufacturing, addressing Preclinical Discovery, Analytical Development, and Process Development teams.

Quantifiable outcome

• Achieved greater than 94% neuronal transduction and 11-fold improvement in brain biodistribution with Dyno-yp2 capsid
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• NanoMosaic, Inc.coreTechnology or Integration · 11 May 2026Partnership to integrate NanoMosaic's Tessie analytics platform into Trisk Bio's AAV process workflows at facilities in Stevenage, England and Waltham, Massachusetts. The integration aims to enhance analytical precision and regulatory compliance for gene therapy manufacturing operations.
• Dyno TherapeuticscoreStrategic or Co-development Partner · 11 November 2025Strategic manufacturing partnership establishing Trisk Bio as the first partner in Dyno Therapeutics' expanded Frontiers Program. This partnership connects gene therapy developers with Trisk's scalable, high-purity AAV production services for Dyno's AI-engineered capsids. The collaboration aims to accelerate gene therapy development and reduce costs for developers using Dyno's capsid technology.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Yposkesi: France-based CDMO specializing in AAV and lentiviral vector manufacturing for gene therapy, with cGMP-compliant production suites. Directly comparable to Trisk Bio as an AAV-focused gene therapy CDMO serving European and US biotech clients.
• PackGene Biotech: AAV CDMO offering scalable viral vector manufacturing services for gene therapy, with platforms supporting multiple serotypes. Comparable to Trisk Bio as an AAV-focused contract manufacturer serving gene therapy developers globally.
• Genezen: US-based viral vector CDMO focused on AAV and lentiviral manufacturing for gene and cell therapy developers, with preclinical through clinical cGMP capabilities. Directly comparable to Trisk Bio's AAV-focused CDMO model.
• Biovian: European (Finland-based) AAV and biopharmaceutical CDMO offering viral vector manufacturing from development through GMP production. Comparable to Trisk Bio as a Europe-based AAV CDMO, though with broader GMP clinical-stage capability.
• Forge Biologics: US-based gene therapy CDMO offering end-to-end AAV and lentiviral manufacturing from process development through cGMP clinical production. Directly comparable to Trisk Bio as an AAV-focused CDMO targeting gene therapy developers, with broader clinical-stage scope.
• Viralgen Vector Core: AAV and lentiviral CDMO based in San Sebastian, Spain (an AskBio subsidiary) offering scalable viral vector manufacturing from preclinical through clinical stages. Directly comparable to Trisk Bio as an AAV-focused contract manufacturer serving gene therapy developers, but with significantly larger capacity and GMP clinical-stage capability.

Broad incumbents

• Aldevron (Danaher): Major manufacturer of plasmids, proteins, and viral vectors (including AAV) for gene therapy developers, now part of Danaher. Comparable to Trisk Bio as an AAV-focused manufacturing services provider, but with significantly broader portfolio and GMP commercial-scale capability.
• AGC Biologics: Large global CDMO with mammalian, microbial, and viral vector (including AAV) manufacturing services across preclinical, clinical, and commercial stages. Comparable as an AAV contract manufacturer with broader service portfolio and established GMP credentials that Trisk Bio lacks.
• Catalent (Paragon Bioservices): Global CDMO with gene therapy viral vector manufacturing capabilities via Paragon Bioservices, serving AAV developers from preclinical through commercial. Comparable to Trisk Bio as an AAV manufacturing services provider, but with vastly larger scale, GMP clinical/commercial capability, and broader customer base.

Emerging players

• VectorBuilder: Custom vector design and manufacturing services company offering AAV, lentiviral, and other viral vectors at research and preclinical scales. Comparable to Trisk Bio as a custom AAV service provider, though broader across vector types and with more of a catalog/research-vector emphasis.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/trisk-bio

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trisk Bio